PMID- 33471684
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210402
IS  - 1530-891X (Print)
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 26
IP  - 8
DP  - 2020 Aug
TI  - Covid-19 & Obesity: Beyond Bmi.
PG  - 923-925
LID - S1530-891X(20)48177-7 [pii]
LID - 10.4158/EP-2020-0302 [doi]
AB  - The pandemic of novel coronavirus disease 2019 (COVID-19) has triggered an 
      international crisis resulting in excess morbidity and mortality with adverse 
      societal, economic, and geopolitical consequences. Like other disease states, 
      there are patient characteristics that impact clinical risk and determine the 
      spectrum of severity. Obesity, or adiposity-based chronic disease, has emerged as 
      an important risk factor for morbidity and mortality due to COVID-19. It is 
      imperative to further stratify risk in patients with obesity to determine optimal 
      mitigation and perhaps therapeutic preparedness strategies. We suspect that 
      insulin resistance is an important pathophysiologic cause of poor outcomes in 
      patients with obesity and COVID-19 independent of body mass index. This explains 
      the association of type 2 diabetes mellitus (T2DM), hypertension (HTN), and 
      cardiovascular disease with poor outcomes since insulin resistance is the main 
      driver of both dysglycemia-based chronic disease and cardiometabolic-based 
      chronic disease towards end-stage disease manifestations. Staging the severity of 
      adiposity-related disease in a "complication-centric" manner (HTN, dyslipidemia, 
      metabolic syndrome, T2DM, obstructive sleep apnea, etc.) among different ethnic 
      groups in patients with COVID-19 should help predict the adverse risk of 
      adiposity on patient health in a pragmatic and actionable manner during this 
      pandemic.
CI  - (c) 2020 American Association of Clinical Endocrinologists. Published by Elsevier, 
      Inc. All rights reserved.
FAU - Nadolsky, Karl Z
AU  - Nadolsky KZ
AD  - From the Department of Diabetes & Endocrinology, Assistant Professor of Medicine, 
      Michigan State University College of Human Medicine, Grand Rapids, Michigan. 
      Electronic address: karl.nadolsky@spectrumhealth.org.
FAU - Hurley, Daniel L
AU  - Hurley DL
AD  - Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Associate 
      Professor of Medicine, Mayo Clinic, Rochester, Minnesota.
FAU - Garvey, W Timothy
AU  - Garvey WT
AD  - Department of Nutrition Sciences, Associate Professor of Medicine, UAB Diabetes 
      Research Center, University of Alabama at Birmingham, Birmingham, Alabama.
LA  - eng
GR  - P30 DK056336/DK/NIDDK NIH HHS/United States
GR  - P30 DK079626/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology 
      and the American Association of Clinical Endocrinologists
JID - 9607439
SB  - IM
MH  - Body Mass Index
MH  - *COVID-19
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Humans
MH  - Obesity/complications/epidemiology
MH  - Risk Factors
MH  - SARS-CoV-2
PMC - PMC7832117
EDAT- 2021/01/21 06:00
MHDA- 2021/01/23 06:00
PMCR- 2020/12/28
CRDT- 2021/01/20 17:09
PHST- 2020/05/18 00:00 [received]
PHST- 2020/06/03 00:00 [accepted]
PHST- 2021/01/20 17:09 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
PHST- 2020/12/28 00:00 [pmc-release]
AID - S1530-891X(20)48177-7 [pii]
AID - 10.4158/EP-2020-0302 [doi]
PST - ppublish
SO  - Endocr Pract. 2020 Aug;26(8):923-925. doi: 10.4158/EP-2020-0302.